Better Treatment Starts with Better Diagnostics

Liquid biopsy reveals immense genetic data from a small sample of blood, without the need for invasive procedures. This opens up more treatment options for patients besides chemotherapy, such as targeted therapies which match patients to drugs associated with specific gene mutations. It also help to detect cancer earlier, and better monitor how the patient is responding to the treatment since a blood test can be easily administered.

Lucence Diagnostics Portfolio

Detect specific gene mutations for a specific cancer.

Detect the Epstein-Barr virus, which causes nasopharyngeal cancer (NPC).

Help identify the suitability of targeted treatments.

Assess the risk of developing multiple cancers in one blood test.

Assess the risk of developing cancer for specific organs.

Using Genomic Data to Drive New Diagnostics Options

Lucence applies powerful data processing methods on DNA sequencing results to generate insights on the patient’s genetic makeup. Our laboratory results are benchmarked with leading quality control agencies to match international standards.

INSIDE A LUCENCE REPORT

Patient Information

Test Summary

Clinical Interpretation and Recommendations

Find out more about other diagnostics including LiquidSCREEN/TRACKTM, LumiRISKTM & LumiFOCUSTM. Contact us for further details.

FREQUENTLY ASKED QUESTIONS

What are genetic mutations and how do they affect cancer?

A genetic mutation is a permanent alteration in the DNA sequence that makes up a gene. They can be classified into 1) hereditary mutations that are inherited from parents and 2) acquired (somatic) mutations that occur in an individual’s lifetime.

The human body’s cell growth is regulated by two groups of genes: proto-oncogenes that promote cell growth and tumor suppressor genes that regulates cell growth. When a mutation occurs in the genes, cell growth is unregulated and it leads to the onset of cancer.

How does cancer genetics help treatment?

Based on clinical studies, certain genetic mutations have been showed to respond better to specific targeted therapies. Understanding the genetics of cancer would allow doctors to match the best treatment options for their patients.

Can Lucence's tests help monitor cancer treatment?

Our somatic cancers tests – LiquidSCREENTM and LiquidTRACKTM can help monitor cancer treatment response in terms of mutation levels as well as the patient’s resistance to the drug therapy.

How fast are the test results back from Lucence?

  • Results are back in 2 working days for somatic tests: LiquidSCREENTM & LiquidTRACKTM.
  • Results are back in 3 weeks for germline test: LumiRISKTM & LumiFOCUSTM.

Does the type and stage of cancer matter with Liquid Biopsy?

Lucence’s Liquid Biopsy tests for certain types of cancers at an early stage and others at a later stage. Please refer to the individual test details for more information.